6. North America Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
6.1. Market Overview
6.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
6.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7. UK and European Union Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
7.1. Market Overview
7.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.5. France
7.3.1.5.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
8.1. Market Overview
8.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.3. India
8.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
9. Latin America Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
9.1. Market Overview
9.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
9.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
10. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
10.1. Market Overview
10.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
10.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
11. Company Profile
11.1. Amgen, Inc.
(Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Achillion Pharmaceuticals
11.3. Alexion Pharmaceutcials, Inc.
11.4. Akari Therapeutics
11.5. Apellis Pharmaceutcials, Inc.
11.6. CinnaGen
11.7. F.Hoffman-La Roche Ltd.
11.8. Novartis AG
11.9. Ra Pharmaceuticals
11.10. Regeneron Pharmaceuticals